• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Nexlizet (bempedoic acid and ezetimibe)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Nexlizet (bempedoic acid and ezetimibe)

  • Profile

Profile

Contact Information

Contact: Esperion Therapeutics
Website: https://www.nexletol.com/nexlizet

Currently Enrolling Trials

    Show More

    General Information

    Nexlizet is an oral, once-daily bempedoic acid 180 mg/ezetimibe 10 mg combination tablet. The combination tablet inhibits 2 key enzymes—ACL and NPC1L1. 

    Nexlizet is specifically indicated with diet and maximally tolerated statins for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional help lowering LDL-C.

    Nexlizet is supplied as a tablet for once daily, oral administration. 

    Mechanism of Action

    Nexlizet is an oral, once-daily bempedoic acid 180 mg/ezetimibe 10 mg combination tablet. Nexlizet inhibits 2 key enzymes—ACL and NPC1L1—and is designed to have two complementary mechanisms of action: Bempedoic acid inhibits cholesterol synthesis via ACL inhibition in the liver. Ezetimibe blocks gastrointestinal cholesterol absorption via NPC1L1 (Niemann-Pick C1-Like 1) inhibition, reducing cholesterol delivery to the liver. These complementary mechanisms are designed to result in LDL receptor upregulation and increased LDL-C clearance from the bloodstream.

    Side Effects

    Adverse effects associated with the use of Nexlizet may include, but are not limited to, the following:

    • upper respiratory tract infection
    • muscle spasms
    • hyperuricemia
    • back pain
    • abdominal pain or discomfort
    • bronchitis
    • pain in the extremities
    • anemia
    • elevated liver enzymes
    • diarrhea
    • arthralgia
    • sinusitis
    • fatigue
    • influenza

    Clinical Trial Results

    The FDA approval of Nexlizet was based on a single, pivotal, Phase 3 bridging study (1002-053) evaluating bempedoic acid 180 mg/ezetimibe 10 mg combination tablet in 382 patients with ASCVD, or at high risk for ASCVD, taking maximally tolerated statin therapy. Safety data was also gathered from the Nexletol tablet global pivotal Phase III LDL-C lowering program and the existing safety profile of ezetimibe. In the trials, Nexlizet decreased LDL-C by a mean of 38% compared to placebo when added to the maximum tolerated dose of statins. The drug was generally well-tolerated.

    Approval Date: 2020-02-01
    Company Name: Esperion Therapeutics
    Back to Listings

    Upcoming Events

    • 16Feb

      Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

    • 21May

      WCG MAGI Clinical Research Conference – 2023 East

    Featured Products

    • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

      Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    Featured Stories

    • SurveywBlueBackground-360x240.png

      Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

    • TrendsInsights2023-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Two

    • TimeMoneyEffort-360x240.png

      Time is Money and So Is Effort, Budgeting Experts Say

    • TrendsInsights2023A-360x240.png

      WCG Clinical Research Trends and Insights for 2023, Part Three

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 617.948.5100 – Toll free 866.219.3440

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing